Abstract： Objective： To observe the clinical effect of Shenwu Yishen Tablets on chronic renal failure (CRF) in early and middle stage with spleen-kidney qi-yin deficiency syndrome. Methods：A total of 78 CRF patients with spleen-kidney qi-yin deficiency syndrome in the early and middle stages admitted to People's Hospital of Anji County from January 2022 to June 2023 were selected. They were divided into the control group and the observation group according to the random number table method， with 39 cases in each group. Both groups were given routine treatment plan， the control group was additionally treated with Compound α-Ketoacid Tablets， and the observation group was additionally treated with Shenwu Yishen Tablets on the basis of the treatment of the control group. Both groups were observed for six months. The kidney function indexes，symptom scores of spleen-kidney qi-yin deficiency syndrome，levels of serum homocysteine (Hcy) and high-sensitivity C-reactive protein (hs-CRP) and clinical effects were compared between the two groups. Results： After six months of treatment， the levels of serum creatinine， urea nitrogen and 24 h urine protein in the two groups were reduced when compared with those before treatment，differences being significant (P＜0.05)；the levels of serum creatinine，urea nitrogen and 24 h urine protein in the observation group were lower than those in the control group， differences being significant (P＜0.05). After six months of treatment， the symptom scores of spleen-kidney qi-yin deficiency syndrome in the two groups were lower than those before treatment， differences being significant (P＜0.05)；the symptom scores of spleen-kidney qi-yin deficiency syndrome in the observation group were lower than those in the control group， the difference being significant (P＜0.05). After six months of treatment，the levels of serum Hcy and hs-CRP in the two groups were down-regulated when compared with those before treatment， differences being significant (P＜0.05)； the levels of serum Hcy and hs-CRP in the observation group were lower than those in the control group， differences being significant (P＜0.05). The total clinical effective rate was 87.18 % in the observation group，and 64.10% in the control group， the difference being significant (P＜0.05). Conclusion： Shenwu Yishen Tablets can improve the kidney function and traditional Chinese medicine syndromes of CRF patients with spleenkidney qi-yin deficiency syndrome in the early and middle stage and down-regulate the levels of serum Hcy and hs-CRP.